Lactobacillus reuteri ATCC PTA 6475
Lactobacillus reuteri ATCC PTA 6475 is a specific probiotic strain that produces reuterin, an antimicrobial compound, to inhibit pathogenic bacteria in the gut. This strain enhances calcium absorption through modulation of intestinal permeability and bone metabolism pathways.

Origin & History
Lactobacillus reuteri ATCC PTA 6475 is a probiotic strain isolated from the human gastrointestinal tract. It is known for its ability to produce reuterin, a compound with antimicrobial properties.
Historical & Cultural Context
Lactobacillus reuteri has been used in traditional fermented foods and probiotics, particularly in Scandinavian cultures, for its health-promoting properties.
Health Benefits
- Supports gut health by inhibiting harmful bacteria, promoting a balanced microbiome. It produces antimicrobial substances that target pathogens. - Enhances bone health by promoting calcium absorption, crucial for maintaining bone density. Studies show a 15% increase in calcium uptake. - Reduces inflammation by modulating immune responses, which can alleviate symptoms of inflammatory conditions. Clinical trials report a 25% reduction in inflammatory markers. - Supports cardiovascular health by lowering blood pressure, contributing to a healthier heart. It helps regulate blood vessel function. - Improves skin health by enhancing the gut-skin axis, leading to clearer and more resilient skin. It reduces oxidative stress and supports skin barrier function. - Aids in weight management by influencing fat metabolism and appetite regulation. It helps reduce body fat percentage. - Enhances mental clarity by supporting the gut-brain axis, which can improve cognitive function and reduce anxiety. Research shows a 20% improvement in mental focus.
How It Works
This strain produces reuterin (3-hydroxypropionaldehyde) through glycerol metabolism, which exhibits broad-spectrum antimicrobial activity against pathogenic bacteria. It modulates tight junction proteins like claudin-1 and zonulin to improve intestinal barrier function. The strain also influences osteoblast activity through increased expression of bone morphogenetic proteins and enhanced calcium transporter TRPV6 expression.
Scientific Research
Lactobacillus reuteri ATCC PTA 6475 has been studied for its effects on bone health and immune function, with promising results in clinical trials.
Clinical Summary
Human studies demonstrate a 15% increase in calcium uptake with supplementation of this specific strain. Clinical trials involving 50-100 participants have shown improved gut microbiome diversity and reduced inflammatory markers after 8-12 weeks of use. Evidence is moderate, with most studies being small-scale randomized controlled trials. Additional research is needed to confirm long-term bone health benefits in larger populations.
Nutritional Profile
- Contains live probiotic bacteria. - Available in capsule, tablet, or liquid form. - Free from artificial colors and preservatives.
Preparation & Dosage
Recommended dosage is 1 to 10 billion CFU per day. Consult a healthcare provider before use.
Synergy & Pairings
Lactobacillus rhamnosus, Omega-3 fatty acids, Calcium
Safety & Interactions
Generally well-tolerated with rare reports of mild digestive upset during initial supplementation. No significant drug interactions have been documented, though timing with antibiotics may reduce probiotic viability. Immunocompromised individuals should consult healthcare providers before use due to theoretical risk of bacteremia. Safety during pregnancy and lactation has not been extensively studied, warranting medical supervision.